HK1205138A1 - Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia cd147 - Google Patents

Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia cd147

Info

Publication number
HK1205138A1
HK1205138A1 HK15105607.7A HK15105607A HK1205138A1 HK 1205138 A1 HK1205138 A1 HK 1205138A1 HK 15105607 A HK15105607 A HK 15105607A HK 1205138 A1 HK1205138 A1 HK 1205138A1
Authority
HK
Hong Kong
Prior art keywords
meningococci
pilus
receptor
mediated adhesion
vascular endothelia
Prior art date
Application number
HK15105607.7A
Other languages
English (en)
Chinese (zh)
Inventor
Xavier Nassif
Sandrine Bourdoulous
Olivier Join-Lambert
Original Assignee
Inst Nat Sant Et De La Rech Md
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sant Et De La Rech Md filed Critical Inst Nat Sant Et De La Rech Md
Publication of HK1205138A1 publication Critical patent/HK1205138A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
HK15105607.7A 2012-07-27 2015-06-12 Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia cd147 HK1205138A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305920 2012-07-27
PCT/EP2013/064900 WO2014016152A1 (fr) 2012-07-27 2013-07-15 Utilisation du cd147 comme récepteur pour l'adhésion impliquant les pili des méningocoques à l'endothélium vasculaire

Publications (1)

Publication Number Publication Date
HK1205138A1 true HK1205138A1 (en) 2015-12-11

Family

ID=48875004

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105607.7A HK1205138A1 (en) 2012-07-27 2015-06-12 Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia cd147

Country Status (8)

Country Link
US (3) US10000545B2 (fr)
EP (1) EP2877492A1 (fr)
JP (1) JP2015524418A (fr)
CN (1) CN104736563A (fr)
AU (1) AU2013295242C1 (fr)
CA (1) CA2875391A1 (fr)
HK (1) HK1205138A1 (fr)
WO (1) WO2014016152A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059593A1 (fr) * 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccins pour la prévention d'infections à méningocoque
EP2877492A1 (fr) * 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Utilisation du cd147 comme récepteur pour l'adhésion impliquant les pili des méningocoques à l'endothélium vasculaire
JP6818358B2 (ja) * 2015-10-29 2021-01-27 国立大学法人山口大学 神経系血管バリアーの機能回復剤及び神経系疾患治療剤
WO2022032099A2 (fr) * 2020-08-06 2022-02-10 Children's Hospital & Research Center At Oakland Variants de protéine de surface de neisseria a (nspa) et leurs procédés d'utilisation

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60240730A (ja) 1984-05-15 1985-11-29 Chisso Corp 可溶性イミドオリゴマーの製法
US4622223A (en) 1984-06-21 1986-11-11 The Board Of Trustees For The Leland Stanford University Broad spectrum vaccine against gonorrhea
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
CA2135646A1 (fr) 1992-05-11 1993-11-25 Kenneth G. Draper Methode et reagent permettant l'inhibition de la replication virale
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US20070202127A1 (en) 1993-06-07 2007-08-30 Duke University Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6518013B1 (en) 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
DE4336530C1 (de) * 1993-10-26 1995-04-13 Max Planck Gesellschaft Rekombinante PilC-Proteine, Verfahren zu ihrer Herstellung und ihre Verwendung
US6620805B1 (en) 1996-03-14 2003-09-16 Yale University Delivery of nucleic acids by porphyrins
WO1997045442A1 (fr) 1996-05-24 1997-12-04 Imperial College Of Science Technology And Medicine Derives polycationiques de sterol en tant qu'agents de transfection
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
CA2294988C (fr) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions et procedes d'apport d'oligonucleotides par le tube digestif
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
AU8525098A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
JP2002505097A (ja) * 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子
JP2003525017A (ja) 1998-04-20 2003-08-26 リボザイム・ファーマシューティカルズ・インコーポレーテッド 遺伝子発現を調節しうる新規な化学組成を有する核酸分子
AU3968599A (en) 1998-04-29 1999-11-16 American Cyanamid Company Vaccines containing recombinant pilin against Neisseria Gonorrhoeae or Neisseria Meningitidis
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
GB9811260D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds
JP2004511201A (ja) 1998-10-09 2004-04-15 カイロン　コーポレイション ナイセリアゲノム配列およびそれらの使用方法
FR2785293B1 (fr) 1998-10-30 2002-07-05 Pasteur Merieux Serums Vacc Acides nucleiques et polypeptides specifiques des souches pathogenes du genre neisseria
US20030215469A1 (en) 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
DK1185691T3 (da) 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
RU2245366C2 (ru) 1999-04-30 2005-01-27 Чирон С.Р.Л. Антиген neisseria, кодирующая его нуклеиновая кислота, их использование
EP2270174A1 (fr) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Compositions à base de combinaisons de Neisseria
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
EP2275552B1 (fr) 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Peptides antigéniques de Neisseria
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
EP1292285A4 (fr) 2000-06-02 2009-07-22 Eisai Corp North America Systemes de distribution d'agents bioactifs
CA2418303A1 (fr) * 2000-08-10 2002-02-21 The Picower Institute For Medical Research Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0107219D0 (en) 2001-03-22 2001-05-16 Microbiological Res Authority Immunogenic commensal neisseria sequences
CA2442261A1 (fr) 2001-03-26 2002-10-03 Alza Corporation Composition de liposome pour une meilleure administration intracellulaire d'un agent therapeutique
US20020192274A1 (en) 2001-03-26 2002-12-19 Ponnappa Biddanda C. pH sensitive liposomal drug delivery
US20030026831A1 (en) 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
CA2445947A1 (fr) 2001-04-30 2002-11-07 Targeted Genetics Corporation Complexes d'administration de medicaments contenant des lipides et leurs methodes de production
DE10127526A1 (de) 2001-05-31 2002-12-12 Novosom Ag Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln
GB0114940D0 (en) 2001-06-19 2001-08-08 Chiron Spa Gene expression during meningococcus adhesion
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
WO2003010194A2 (fr) 2001-07-27 2003-02-06 Chiron Srl. Adhesines des meningocoques
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
US7838015B2 (en) 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE10152145A1 (de) 2001-10-19 2003-05-22 Novosom Ag Stabilisierung von Liposomen und Emulsionen
EP2325193A3 (fr) 2001-11-02 2012-05-02 Insert Therapeutics, Inc. Procédés et compositions permettant l'utilisation thérapeutique de l'interférence ARN
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
FR2834297A1 (fr) 2001-12-31 2003-07-04 Inst Nat Sante Rech Med Moyens pour identifier des genes specifiques de neisseria meningitidis
WO2003057190A1 (fr) 2001-12-31 2003-07-17 Elan Pharmaceuticals, Inc. Encapsulation efficace d'acides nucleiques dans des liposomes de taille moyenne
AU2003205384A1 (en) 2002-02-01 2003-09-02 Intradigm Corporation Polymers for delivering peptides and small molecules in vivo
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
CN1305932C (zh) 2002-02-22 2007-03-21 植入疗法公司 碳水化合物修饰的聚合物、其组合物及其应用
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
WO2003083443A2 (fr) 2002-03-29 2003-10-09 University Of Florida Criblage a base de lipides de medicaments candidats, destine a l'identification de composes actifs
ES2328031T3 (es) 2002-05-24 2009-11-06 F. Hoffmann-La Roche Ag Composiciones para distribuir acidos nucleicos a celulas.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004032958A1 (fr) 2002-10-11 2004-04-22 Chiron Srl Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
EP2279746B1 (fr) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Proteines de surface de neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004065603A2 (fr) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methodes d'augmentation de l'expression de la proteine neisseria et compositions associees
WO2004067030A2 (fr) 2003-01-30 2004-08-12 Chiron Srl Vaccins injectables contre les multiples serogroupes du meningocoque
US7682626B2 (en) 2003-02-07 2010-03-23 Roche Madison Inc. Polyvinylethers for delivery of polynucleotides to mammalian cells
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
EP1618185A4 (fr) 2003-04-16 2009-05-27 Wyeth Corp Nouvelles compositions immunogenes de prevention de traitement de meningococcie
GB0315022D0 (en) 2003-06-26 2003-07-30 Chiron Srl Virulence-associated adhesins
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
AR045815A1 (es) 2003-10-09 2005-11-16 Ct Ingenieria Genetica Biotech Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
CU23459A1 (es) 2003-11-19 2009-12-01 Ct Ingenieria Genetica Biotech Método de aislamiento selectivo de péptidos para la identificación y análisis cuantitativo de proteínas en mezclas complejas
KR101178776B1 (ko) 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0415160D0 (en) 2004-07-06 2004-08-11 Chiron Srl Inhibitors of bacterial infection
CN101014618B (zh) 2004-07-23 2013-01-02 诺华疫苗和诊断有限公司 抗原的寡聚装配多肽
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US20090162400A1 (en) 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
EP1841785A2 (fr) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprenant motifs moleculaires associes a des agents pathogenes et des antigenes et leur utilisation pour stimuler la reponse immunitaire
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
CA2615617A1 (fr) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Agents de transport utiles pour traverser la barriere hemato-encephalique et pour penetrer dans les cellules cancereuses du cerveau, methodes d'utilisation de ces derniers
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2632434A1 (fr) 2005-12-06 2007-06-14 Universita Degli Studi Di Padova Methodes et compositions relatives a des adhesines servant d'adjuvants
EP2476432B1 (fr) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions incluant de l'hémagglutinine, procédés pour leur fabrication et leurs méthodes d'utilisation
CN101479293A (zh) 2006-06-29 2009-07-08 诺华有限公司 脑膜炎奈瑟球菌多肽
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008125985A2 (fr) 2007-04-11 2008-10-23 Novartis Ag Interaction de blocage entre des facteurs pathogènes et le facteur h pour inhiber des syndromes hémorragiques
JP5701058B2 (ja) 2007-10-19 2015-04-15 ノバルティス アーゲー 髄膜炎菌ワクチン処方物
US20100029168A1 (en) 2007-10-26 2010-02-04 Fleming James S Toy block
WO2009073133A1 (fr) 2007-11-29 2009-06-11 Vaxinnate Corporation Compositions à base d'agonistes des récepteurs de type toll et d'antigènes du papillomavirus et leurs procédés d'utilisation
WO2009074867A2 (fr) 2007-12-10 2009-06-18 Novartis Ag Analyse de mélanges comprenant des protéines
WO2009082440A2 (fr) 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions d'agonistes de recepteurs de type toll et d'antigènes de la malaria et procédés d'utilisation correspondants
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
US8466167B2 (en) 2008-03-03 2013-06-18 Irm Llc Compounds and compositions as TLR activity modulators
EP2631245A1 (fr) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Protéines chimères de liaison du facteur H contenant un domaine B hétérologue, et procédés d utilisation associés
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
GB0809659D0 (en) 2008-05-28 2008-07-02 Univ Nottingham Polypeptides
WO2009150531A1 (fr) 2008-06-09 2009-12-17 Novartis Ag Anticorps dirigés contre la protéine de neisseria liant le facteur h
EP2313085A2 (fr) 2008-07-15 2011-04-27 Novartis AG Compositions de peptides amphipatiques immunogènes
US20110280949A1 (en) 2008-08-06 2011-11-17 Padma Malyala Microparticles for use in immunogenic compositions
CN102216768A (zh) 2008-09-09 2011-10-12 由卫生福利和体育大臣代表的荷兰王国 Lcms技术及其应用
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
US20100151151A1 (en) 2008-12-11 2010-06-17 Asm Japan K.K. Method of forming low-k film having chemical resistance
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2756398A1 (fr) 2009-03-24 2010-09-30 Novartis Ag Combinaisons comprenant un saccharide de pneumocoque serotype 14
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
CA2756533A1 (fr) 2009-03-24 2010-09-30 Novartis Ag Combinaisons de proteine liant le facteur h de meningocoque et de conjugues de saccharide de pneumocoque
US20100318782A1 (en) 2009-06-12 2010-12-16 Microsoft Corporation Secure and private backup storage and processing for trusted computing and data services
JP2013503148A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
WO2011024072A2 (fr) 2009-08-27 2011-03-03 Novartis Ag Polypeptides hybrides contenant des séquences fhbp à méningocoques
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
GB0915403D0 (en) 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
WO2012059593A1 (fr) * 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccins pour la prévention d'infections à méningocoque
WO2013113326A1 (fr) 2012-01-31 2013-08-08 Curevac Gmbh Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide
EP2877492A1 (fr) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Utilisation du cd147 comme récepteur pour l'adhésion impliquant les pili des méningocoques à l'endothélium vasculaire

Also Published As

Publication number Publication date
AU2013295242B2 (en) 2018-04-05
US20150110806A1 (en) 2015-04-23
CA2875391A1 (fr) 2014-01-30
WO2014016152A1 (fr) 2014-01-30
US20190389927A1 (en) 2019-12-26
EP2877492A1 (fr) 2015-06-03
AU2013295242A1 (en) 2015-01-15
AU2013295242B9 (en) 2018-05-17
CN104736563A (zh) 2015-06-24
US20180340017A1 (en) 2018-11-29
JP2015524418A (ja) 2015-08-24
US10000545B2 (en) 2018-06-19
AU2013295242C1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
HK1256896A1 (zh) 用於實現多重cold-pcr的方法和組合物
HK1198358A1 (en) Sustained release composition of prostacyclin
IL228001A0 (en) Antibodies to 70cd
IL229830B (en) Novel compinds as modulatord of gpr-119
SG11201403003SA (en) Structural adhesive compositions
EP2855745A4 (fr) Méthodes associées à l'adalimumab
EP2571530A4 (fr) Procédés et compositions liés à la modulation de l'autophagie
SG2014013510A (en) Interfaces to manage direct network peerings
ZA201400330B (en) Novel composition
EP2737311A4 (fr) Dosages pour la surveillance de troubles hémostatiques
EP2917314A4 (fr) Composition d'oligomère
HK1192323A1 (zh) -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途
GB2489486B (en) Improvements relating to construction
HK1203355A1 (en) Uses of 4-desferrithiocin analogs 4-
HK1205138A1 (en) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia cd147
EP2531961A4 (fr) Techniques permettant de mettre en correspondance des cours avec des exigences de programme
PL2583571T3 (pl) Ulepszenia dotyczące czapsów
EP2904119A4 (fr) Procédés associés à des états associés à la voie de la détection de l'adn
PL2663198T3 (pl) Kompozycje związane z karotenoidami
GB201008275D0 (en) Improvements relating to displays
GB201121300D0 (en) Novel composition
GB201116456D0 (en) Improvements relating to foorwear
GB201120175D0 (en) TO component seal
GB201220224D0 (en) Improvements relating to audio visual interfaces
GB201215288D0 (en) Improvements relating to firelighters